Scienture Holdings (SCNX) Research & Development (2025 - 2026)
Scienture Holdings' (SCNX) quarterly Research & Development came in at $1.2 million in Q2 2026, up 38.3% year-over-year from $843549.0 in Q2 2025, and up 46.93% quarter-over-quarter from $793984.0 in Q1 2026.
Powered by 
Analysis
Scienture Holdings (SCNX) Research & Development (2025 - 2026) Analysis & Trends
Scienture Holdings has disclosed Research & Development across 2 years of filings, most recently posting $1.2 million for Q2 2026.
- In Q2 2026, Research & Development rose 38.3% year-over-year to $1.2 million; the TTM figure through Jun 2026 stood at $3.4 million (changed N/A YoY), while the FY2025 annual figure was $2.0 million, down 12.54% from the prior year.
- Research & Development came in at $1.2 million for Q2 2026 at Scienture Holdings, up from $793984.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $1.2 million in Q2 2026 to a low of $574679.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | 970.00 Mn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | 248.30 Mn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | 60.90 Mn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 39.02 Mn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | 173.00 Mn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | 14.75 Mn |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | -21.86 Mn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | 22.16 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | 10.66 Mn |
| 10 | Scienture Holdings | 15.19 Mn | 15.19 Mn | 335,779.00 | 1.17 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.17 Mn |
| Mar 31, 2026 | 793,984.00 |
| Jun 30, 2025 | 843,549.00 |
| Mar 31, 2025 | 574,679.00 |